Related Experiment Videos
Somatostatin receptors and disease: role of receptor subtypes
1Department of Internal Medicine III, Erasmus University, Rotterdam, The Netherlands.
Abstract:
A variety of human neuroendocrine tumours express SSTR. The five recently cloned human SSTR subtypes have a distinct chromosomal localization and pharmacological profile, and a tissue-specific expression pattern which suggests a differential function of SSTR subtypes in different organ systems. Most tumours carrying SSTR may express multiple SSTR subtypes, while the SSTR2 subtype is most predominantly expressed. The somatostatin analogue, octreotide, binds with high affinity to the SSTR2 and SSTR5 subtype and with a low affinity to the SSTR3 subtype. This analogue does not bind to the SSTR1 and SSTR4 subtypes. No major differences in the binding characteristics have been found between octreotide and two other clinically used octapeptide SST-analogues, BIM-23014 and RC-160. Our preliminary data indicate that an absent hormonal response to octreotide in vitro also implies an absent response to BIM-23014 and RC-160. The expression of the SSTR2 subtype in human tumours is proposed to be related to a clinical beneficial effect of octreotide treatment, while the functional significance of the other SSTR subtypes is not clear at present. In addition it is unclear which subtype(s) is involved in the antimitotic actions of SST(-analogues). Further developments with regard to the oncological application of SST analogues await the identification of the SSTR subtype(s) mediating anti-proliferative effects, as well as the development of analogues which selectively activate this subtype(s). A good correlation has been found between the presence of SSTR2 subtype mRNA and binding of [125I-Tyr3]octreotide in human primary tumours. Therefore, SSTR scintigraphy of human primary tumours and their metastases presumably visualizes SSTR2-expressing tumours, although it is reasonable to assume that SSTR5, and to a lesser extent SSTR3, when expressed simultaneously with SSTR2, also contribute to the visualization of tumours.
Insights
Neuroendocrine tumors often express somatostatin receptor 2 (SSTR2), a key target for octreotide therapy. SSTR2 expression correlates with treatment benefits and tumor visualization via scintigraphy.
Area of Science:
- Endocrinology
- Oncology
- Molecular Biology
Background:
- Human neuroendocrine tumors frequently express somatostatin receptors (SSTRs).
- Five SSTR subtypes exist, each with unique localization, pharmacology, and expression patterns, suggesting diverse functions.
- SSTR2 is the most commonly expressed subtype in tumors, though multiple subtypes can be present.
Purpose of the Study:
- To investigate the differential expression and functional significance of SSTR subtypes in human neuroendocrine tumors.
- To evaluate the binding characteristics of octreotide and other somatostatin analogues to various SSTR subtypes.
- To determine the role of specific SSTR subtypes in the anti-proliferative effects of somatostatin analogues for oncological applications.
Main Methods:
- Analysis of SSTR subtype expression in human neuroendocrine tumors.
- Pharmacological characterization of octreotide and related analogues binding to SSTR subtypes.
- Correlation of SSTR2 expression with in vitro hormonal response and in vivo tumor visualization.
Main Results:
- Octreotide binds with high affinity to SSTR2 and SSTR5, and low affinity to SSTR3; it does not bind to SSTR1 or SSTR4.
- Octreotide, BIM-23014, and RC-160 exhibit similar binding characteristics, and lack of response to one implies lack of response to others.
- A strong correlation exists between SSTR2 subtype mRNA presence and [125I-Tyr3]octreotide binding in primary tumors, suggesting SSTR2 is visualized in scintigraphy.
Conclusions:
- SSTR2 expression is likely linked to the clinical benefits of octreotide treatment in neuroendocrine tumors.
- The precise role of other SSTR subtypes and their involvement in the anti-proliferative actions of somatostatin analogues require further investigation.
- Identifying SSTR subtypes mediating anti-proliferative effects is crucial for developing targeted therapies and improving oncological applications of somatostatin analogues.